Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Mult Scler
    September 2025
  1. UYSAL TAN F, Tan MO
    Comment on 'short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis'.
    Mult Scler. 2025 Sep 22:13524585251380003. doi: 10.1177/13524585251380003.
    >> Share

  2. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Response to the letter by Uysal Tan and Tan regarding our article "short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis".
    Mult Scler. 2025 Sep 22:13524585251380411. doi: 10.1177/13524585251380411.
    >> Share

  3. SHIPLEY J, Beadnall HN, Sanfilippo PG, Horakova D, et al
    Disease course after pregnancy in women with progressive multiple sclerosis symptoms.
    Mult Scler. 2025 Sep 20:13524585251368248. doi: 10.1177/13524585251368248.
    >> Share

  4. SALAZAR-CAMELO A, Vega L, Fadlallah Y, Bou Rjeily N, et al
    Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls.
    Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.
    >> Share

  5. GERNERT JA, Klein M, Schoberl F, Muller KJ, et al
    Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.
    Mult Scler. 2025 Sep 11:13524585251369425. doi: 10.1177/13524585251369425.
    >> Share

  6. TOUBASI A, Hett K, Xu J, Gheen C, et al
    Parasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis.
    Mult Scler. 2025 Sep 10:13524585251364720. doi: 10.1177/13524585251364720.
    >> Share

  7. PONZANO M, Fedriga MM, Signori A, Bergamaschi R, et al
    Social determinants of health in multiple sclerosis in Italy: A scoping review.
    Mult Scler. 2025 Sep 10:13524585251353196. doi: 10.1177/13524585251353196.
    >> Share

  8. ZHAO-FLEMING HH, Decker PA, Kosel ML, Drucker KL, et al
    Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination.
    Mult Scler. 2025 Sep 8:13524585251371984. doi: 10.1177/13524585251371984.
    >> Share

  9. LARONI A, Vigo T, Inglese M, Uccelli A, et al
    Immunosenescence in multiple sclerosis: New insights and clinical implications.
    Mult Scler. 2025 Sep 2:13524585251367611. doi: 10.1177/13524585251367611.
    >> Share

  10. LI J, Hutton GJ, Aparasu RR
    Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
    Mult Scler. 2025 Sep 2:13524585251368687. doi: 10.1177/13524585251368687.
    >> Share

  11. TOUBASI AA, Graham M, Cutter G, Gheen C, et al
    Comparing the macromolecular-to-free pool size ratio and the magnetization transfer ratio for the assessment of myelin injury in early multiple sclerosis.
    Mult Scler. 2025 Sep 1:13524585251364766. doi: 10.1177/13524585251364766.
    >> Share

  12. KOUKOU G, Bartels F, Aigner A, Cleaveland R, et al
    Reduced brain volumes in children with radiologically isolated syndrome.
    Mult Scler. 2025;31:1195-1204.
    >> Share

  13. SHIBAHARA T, Yamanaka K, Matsuoka M, Tachibana M, et al
    A case of neuromyelitis optica spectrum disorder complicated with aquaporin-4-antibody-associated organizing pneumonia.
    Mult Scler. 2025;31:1254-1257.
    >> Share

    August 2025
  14. BRUNO A, Greco R
    Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? No.
    Mult Scler. 2025 Aug 29:13524585251364144. doi: 10.1177/13524585251364144.
    >> Share

  15. MASSEY J, Monif M
    Anti-B-cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Commentary.
    Mult Scler. 2025 Aug 29:13524585251370085. doi: 10.1177/13524585251370085.
    >> Share

  16. DERSCH R, Wiendl H
    'Anti-B cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation': Yes.
    Mult Scler. 2025 Aug 29:13524585251364140. doi: 10.1177/13524585251364140.
    >> Share

  17. BRIGGS FB, Genuario I, De Nadai AS, Gunzler DD, et al
    Predicting suicidal ideation at subsequent clinical encounter in multiple sclerosis patients.
    Mult Scler. 2025 Aug 25:13524585251365207. doi: 10.1177/13524585251365207.
    >> Share

  18. ZHAO DH, Hadley G, Pisa M, Saunders P, et al
    Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage.
    Mult Scler. 2025 Aug 20:13524585251365791. doi: 10.1177/13524585251365791.
    >> Share

  19. KRAJNC N, Ponleitner M, Fottinger F, Leutmezer F, et al
    Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis.
    Mult Scler. 2025 Aug 19:13524585251360972. doi: 10.1177/13524585251360972.
    >> Share

  20. KRAUSE N, Derad C, von Glasenapp B, Riemann-Lorenz K, et al
    Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.
    Mult Scler. 2025 Aug 12:13524585251356410. doi: 10.1177/13524585251356410.
    >> Share

  21. JOKUBAITIS VG, Alroughani R, Altintas A, Eichau S, et al
    Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
    Mult Scler. 2025;31:1088-1101.
    >> Share

  22. KANG YR, Ju H, Kim KH, Choo SH, et al
    Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2025;31:1102-1109.
    >> Share

    July 2025
  23. AXHAUSEN F, Mrochen A, Winter P, Baumgart R, et al
    Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis.
    Mult Scler. 2025 Jul 30:13524585251361330. doi: 10.1177/13524585251361330.
    >> Share

  24. CELLERINO M, Massarotti C, Peluffo C, Sirito T, et al
    Relationship between ovarian reserve and disease activity in women with multiple sclerosis.
    Mult Scler. 2025 Jul 28:13524585251356384. doi: 10.1177/13524585251356384.
    >> Share

  25. ASP AJ, Jahanian O, Gill ML, Veith DD, et al
    Percutaneous epidural spinal cord stimulation immediately reduces clonus in an individual with multiple sclerosis.
    Mult Scler. 2025 Jul 28:13524585251357143. doi: 10.1177/13524585251357143.
    >> Share

  26. FEYS P, Lamers I, Kos D, Reebye R, et al
    Embracing the complexity of rehabilitation in multiple sclerosis empowered by the resolution of the World Health Organization.
    Mult Scler. 2025 Jul 23:13524585251356967. doi: 10.1177/13524585251356967.
    >> Share

  27. COHEN JA, Arnold DL, DeLuca J, Hartung HP, et al
    Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
    Mult Scler. 2025 Jul 23:13524585251355842. doi: 10.1177/13524585251355842.
    >> Share

  28. LEBRUN-FRENAY C, Okuda DT
    High-risk populations should be screened for multiple sclerosis: No.
    Mult Scler. 2025 Jul 8:13524585251353025. doi: 10.1177/13524585251353025.
    >> Share

  29. BECZEK A, Landt EM, Magyari M, Storr LK, et al
    Assessing the association between mortality and clinical follow-up visits in multiple sclerosis.
    Mult Scler. 2025 Jul 7:13524585251353079. doi: 10.1177/13524585251353079.
    >> Share

  30. BOFFA G, Genchi A, Mariottini A, Brittain G, et al
    Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Mult Scler. 2025 Jul 7:13524585251349129. doi: 10.1177/13524585251349129.
    >> Share

  31. AFFINITO G, Moccia M, Lanzillo R, Marrie RA, et al
    Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
    Mult Scler. 2025 Jul 3:13524585251347513. doi: 10.1177/13524585251347513.
    >> Share

  32. TORO J, Gaitan J, Lago J, Groot H, et al
    The association of HLA-DQB1*04 and DQB1*03 with neuromyelitis optica spectrum disorders: A case-control study considering genetic ancestry.
    Mult Scler. 2025;31:922-931.
    >> Share

    June 2025
  33. CRUZ RIVERA S, Buxhoeveden S, Aiyegbusi OL, Bozinov N, et al
    The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.
    Mult Scler. 2025 Jun 29:13524585251349354. doi: 10.1177/13524585251349354.
    >> Share

  34. BALSHI A, Dempsey JP, Manning N, Leuenberger G, et al
    Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
    Mult Scler. 2025 Jun 25:13524585251342725. doi: 10.1177/13524585251342725.
    >> Share

  35. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis.
    Mult Scler. 2025 Jun 19:13524585251345317. doi: 10.1177/13524585251345317.
    >> Share

  36. ARAB BAFRANI M, Rios V, Kim MJ, Balan A, et al
    Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis.
    Mult Scler. 2025 Jun 18:13524585251346371. doi: 10.1177/13524585251346371.
    >> Share

  37. SAHU M, Chomba M, Mortel D, Braun S, et al
    Factors associated with delay to diagnosis of multiple sclerosis in Zambia.
    Mult Scler. 2025 Jun 17:13524585251344832. doi: 10.1177/13524585251344832.
    >> Share

  38. BEREK K, Schmidauer M, Bsteh G, Auer M, et al
    Kappa free light chain index predicts long-term disease activity and disability accrual in multiple sclerosis.
    Mult Scler. 2025 Jun 16:13524585251344807. doi: 10.1177/13524585251344807.
    >> Share

  39. STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al
    Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
    Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
    >> Share

  40. MOCCIA M
    Clinical commentary to gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177.
    >> Share

  41. NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al
    Gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174.
    >> Share

  42. VARLEY J, Beyrouti R, Nicholas R, Dorsey R, et al
    A comparison of JC virus assay performance provided with originator and biosimilar natalizumab.
    Mult Scler. 2025;31:882-885.
    >> Share

  43. VUKUSIC S, Hubben F, Gavoille A, Malek Y, et al
    Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?
    Mult Scler. 2025;31:877-881.
    >> Share

  44. GARTHOF S, Schafer S, Elmers J, Schwed L, et al
    Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.
    Mult Scler. 2025;31:856-865.
    >> Share

  45. LEAVITT VM, Fox R, Mostert J, D'Haeseleer M, et al
    Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study.
    Mult Scler. 2025;31:866-876.
    >> Share

  46. ARNOLD DL, Kolind S, Assemlal HE, Bar-Or A, et al
    Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
    Mult Scler. 2025;31:821-832.
    >> Share

    May 2025
  47. NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al
    Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.
    Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794.
    >> Share

  48. VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al
    Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
    Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115.
    >> Share

  49. FOONG YC, Butzkueven H
    Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? - No.
    Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805.
    >> Share

  50. ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al
    Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
    Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727.
    >> Share

  51. ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al
    Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
    Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841.
    >> Share

  52. ZANE GK, Sutton A, Brumwell A, Hossain MR, et al
    The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
    Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812.
    >> Share

  53. MARRIE RA, Maxwell CJ, Everett K, Zhu F, et al
    Health care use preceding pediatric multiple sclerosis: A population-based study from Ontario, Canada.
    Mult Scler. 2025 May 23:13524585251338745. doi: 10.1177/13524585251338745.
    >> Share

  54. MACCARRONE D, Prados F, Ciccarelli O
    The relationship between cladribine and reduced regional grey matter volume loss in people with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772.
    >> Share

  55. LOREFICE L, Zivadinov R
    Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
    Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750.
    >> Share

  56. GRESELIN M, Lu PJ, Mroczek M, Cerda-Fuertes N, et al
    AI-assisted identification of disability patterns within identical EDSS grades.
    Mult Scler. 2025;31:677-688.
    >> Share

  57. FOX RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, et al
    Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.
    Mult Scler. 2025;31:706-718.
    >> Share

  58. LEE A, Iordanova RT, Smith JB, Li BH, et al
    Incidence and prevalence of neuromyelitis optica spectrum disorder in a contemporary, multi-ethnic cohort.
    Mult Scler. 2025;31:642-657.
    >> Share

  59. CHAN F, Berhanu D, Samadzadeh S, Francis A, et al
    Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.
    Mult Scler. 2025;31:658-667.
    >> Share

    April 2025
  60. YALDIZLI O, Benkert P, Achtnichts L, Bar-Or A, et al
    Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.
    Mult Scler. 2025 Apr 28:13524585251335466. doi: 10.1177/13524585251335466.
    >> Share

  61. STEPHENS S, Iseyas N, Yeh EA
    Physical activity demonstrates protective associations with structural visual metrics in children with multiple sclerosis through time.
    Mult Scler. 2025 Apr 28:13524585251335510. doi: 10.1177/13524585251335510.
    >> Share

  62. PILOTTO S, Pontieri L, Nielsen HH, Rasmussen PV, et al
    Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR).
    Mult Scler. 2025 Apr 28:13524585251335476. doi: 10.1177/13524585251335476.
    >> Share

  63. MADILL E, Moreira Ferreira V, Healy B, Zurawski J, et al
    Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis.
    Mult Scler. 2025 Apr 28:13524585251335521. doi: 10.1177/13524585251335521.
    >> Share

  64. FERRAZZANO G, Maccarrone D, Guerra A, Collura A, et al
    The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study.
    Mult Scler. 2025 Apr 26:13524585251333575. doi: 10.1177/13524585251333575.
    >> Share

  65. GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al
    Differential Validity in the Written, Oral, and Electronic SDMT in Multiple Sclerosis.
    Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961.
    >> Share

  66. KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al
    Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in identifying optic neuritis in multiple sclerosis.
    Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895.
    >> Share

  67. MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al
    Risk factors for incident peripartum mental illness in multiple sclerosis.
    Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109.
    >> Share

  68. MACARON G, Farah N, Charbonneau S, Morrow SA, et al
    Addressing patient-reported cognitive impairment in multiple sclerosis clinical practice: A challenging endeavor.
    Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488.
    >> Share

  69. FADLALLAH Y, Wang Y, Malik MT, Tian F, et al
    Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405.
    >> Share

  70. JENSEN MP, Robles S, Nash MG, May S, et al
    Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study.
    Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820.
    >> Share

  71. EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al
    Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
    Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499.
    >> Share

  72. BSTEH G, Hegen H, Albrecht P, Havla J, et al
    Emphasizing complementary in "Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis".
    Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800.
    >> Share

  73. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
    Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787.
    >> Share

  74. LIU X, Wang Y, Wei N, Zhu W, et al
    The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study.
    Mult Scler. 2025 Apr 12:13524585251328902. doi: 10.1177/13524585251328902.
    >> Share

  75. REVIE L, Jurjens A, Eveslage M, Trumpelmann S, et al
    Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab.
    Mult Scler. 2025 Apr 3:13524585251329849. doi: 10.1177/13524585251329849.
    >> Share

  76. SAYLOR D, Rijke N, McDonell J, Laurson-Doube J, et al
    Recommendations for essential medicines for multiple sclerosis in low-resource settings.
    Mult Scler. 2025;31:464-473.
    >> Share

  77. BARANZINI SE
    The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS.
    Mult Scler. 2025;31:384-391.
    >> Share

  78. MERLO D, Ja J, Foong YC, Zhu C, et al
    Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.
    Mult Scler. 2025 Apr 1:13524585251329035. doi: 10.1177/13524585251329035.
    >> Share

  79. BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al
    Incidence of optic neuritis among Afro-descendant, a cohort study.
    Mult Scler. 2025;31:529-538.
    >> Share

  80. BUDHRAM A, Flanagan EP
    Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how.
    Mult Scler. 2025;31:505-511.
    >> Share

  81. SONI RH, Garcia M, Oak E, Applbaum EJ, et al
    Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD.
    Mult Scler. 2025;31:612-614.
    >> Share

  82. TOMMASO G, Damiano P, Pietro I
    Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report.
    Mult Scler. 2025;31:615-617.
    >> Share

  83. LAAKSO SM, Oh J, Raufdeen F, Jones A, et al
    Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
    Mult Scler. 2025;31:607-611.
    >> Share

    March 2025
  84. CIAMPI E, Garcia L, Carcamo C, Soler B, et al
    Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.
    Mult Scler. 2025 Mar 29:13524585251329159. doi: 10.1177/13524585251329159.
    >> Share

  85. LEVIT E, Cohen I, Mahajan A, Ulano A, et al
    Evaluation of the relationship between brainstem lesions and apnea hypopnea index in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 29:13524585251327875. doi: 10.1177/13524585251327875.
    >> Share

  86. NOROOZI R, Tsai HH, Yu K, Bronson P, et al
    Metabolic and lipid alterations in multiple sclerosis linked to disease severity.
    Mult Scler. 2025 Mar 27:13524585251325468. doi: 10.1177/13524585251325468.
    >> Share

  87. LIU X, Zhang C
    Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324854. doi: 10.1177/13524585251324854.
    >> Share

  88. SIMANI L, Leavitt VM
    Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Mar 27:13524585251324872. doi: 10.1177/13524585251324872.
    >> Share

  89. BAKIRTZIS C, Dimitriou N, Moysiadis T, El-Wahsh S, et al
    Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status.
    Mult Scler. 2025 Mar 20:13524585251328556. doi: 10.1177/13524585251328556.
    >> Share

  90. FREEDMAN DE, Oh J, Meza C, Feinstein A, et al
    Seizure history and cognitive dysfunction in people with multiple sclerosis.
    Mult Scler. 2025 Mar 18:13524585251326841. doi: 10.1177/13524585251326841.
    >> Share

  91. WILLIAMS J, Marin WM, Wade KJ, Suseno R, et al
    Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis.
    Mult Scler. 2025 Mar 15:13524585251324850. doi: 10.1177/13524585251324850.
    >> Share

  92. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.
    Mult Scler. 2025 Mar 13:13524585251323178. doi: 10.1177/13524585251323178.
    >> Share

  93. CARVAJAL R, Tur C, Borras-Bermejo B, Saylor D, et al
    Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.
    Mult Scler. 2025 Mar 12:13524585251318513. doi: 10.1177/13524585251318513.
    >> Share

  94. MAILLART E, Rollot F, Leray E, Benyahya L, et al
    Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population.
    Mult Scler. 2025;31:324-337.
    >> Share

  95. ZEYDAN B, Son J, Neyal N, Schwarz CG, et al
    Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
    Mult Scler. 2025;31:278-289.
    >> Share

  96. LEBRUN-FRENAY C
    The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives.
    Mult Scler. 2025;31:249-256.
    >> Share

  97. AL GBURI M, Mazzola M, Absinta M, Gaitan MI, et al
    Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter.
    Mult Scler. 2025;31:263-277.
    >> Share

  98. RAMDANI R, Pique J, Deschamps R, Ciron J, et al
    Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.
    Mult Scler. 2025;31:290-302.
    >> Share

    February 2025
  99. STOGBAUER J, Schegerer V, Berger FK, Schulz-Schaeffer W, et al
    Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report.
    Mult Scler. 2025 Feb 27:13524585251322327. doi: 10.1177/13524585251322327.
    >> Share

  100. BALSHI A
    Climate change and multiple sclerosis: Clinical challenges and strategies.
    Mult Scler. 2025 Feb 26:13524585251322664. doi: 10.1177/13524585251322664.
    >> Share

  101. GOGA JJ, Ginell KM, Ng YT, Ehde DM, et al
    Feasibility, reliability, and validity of ambulatory smartphone-administered cognitive tests in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251320814. doi: 10.1177/13524585251320814.
    >> Share

  102. BARRANTES-CEPAS M, Noteboom S, Colato E, Battaglini M, et al
    Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.
    Mult Scler. 2025 Feb 25:13524585251314779. doi: 10.1177/13524585251314779.
    >> Share

  103. DELUCA J
    An interdisciplinary approach is necessary in the treatment of cognitive decline in Multiple Sclerosis: Commentary.
    Mult Scler. 2025 Feb 25:13524585251315357. doi: 10.1177/13524585251315357.
    >> Share

  104. DONKERS SJ, Walker LA
    An interdisciplinary approach is necessary in the treatment of cognitive decline in multiple sclerosis - YES.
    Mult Scler. 2025 Feb 25:13524585251315344. doi: 10.1177/13524585251315344.
    >> Share

  105. SCHOEPS VA, Smith JB, Langer-Gould A
    Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility.
    Mult Scler. 2025 Feb 19:13524585251318293. doi: 10.1177/13524585251318293.
    >> Share

  106. LINDBERG S, Sandgren S, Axelsson M, Rosenstein I, et al
    Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.
    Mult Scler. 2025 Feb 18:13524585251318516. doi: 10.1177/13524585251318516.
    >> Share

  107. KARATSIDIS A, Angelini L, Scaramozza M, Bartholome E, et al
    Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.
    Mult Scler. 2025 Feb 18:13524585251316242. doi: 10.1177/13524585251316242.
    >> Share

  108. MITRACHE DESAGA AC, Noui Y, Silfverberg T, Carlson K, et al
    Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2025 Feb 17:13524585251315363. doi: 10.1177/13524585251315363.
    >> Share

  109. SIMONSEN CS, Flemmen HO, Broch L, Brekke K, et al
    Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.
    Mult Scler. 2025 Feb 17:13524585251315077. doi: 10.1177/13524585251315077.
    >> Share

  110. VAVASOUR I, Elliott C, Arnold DL, Gaetano L, et al
    Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.
    Mult Scler. 2025 Feb 14:13524585251316519. doi: 10.1177/13524585251316519.
    >> Share

  111. ALBERGONI M, Preziosa P, Meani A, Dallari C, et al
    Aerobic capacity moderates the association between cervical cord atrophy and clinical disability in mildly disabled multiple sclerosis patients.
    Mult Scler. 2025 Feb 14:13524585251318647. doi: 10.1177/13524585251318647.
    >> Share

  112. MARRODAN M, Sao Aviles A, Rio J, Cobo-Calvo A, et al
    Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.
    Mult Scler. 2025 Feb 10:13524585251316471. doi: 10.1177/13524585251316471.
    >> Share

  113. VILASECA A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, et al
    Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.
    Mult Scler. 2025 Feb 5:13524585251314749. doi: 10.1177/13524585251314749.
    >> Share

  114. SUMOWSKI JF, Sandry J
    Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty.
    Mult Scler. 2025 Feb 2:13524585241309805. doi: 10.1177/13524585241309805.
    >> Share

  115. TAUL-MADSEN L, Hvid LG, Riis H, Brolos MK, et al
    A head-to-head comparison of the effects of aerobic versus resistance training on physical capacity and physical function in people with multiple sclerosis: Results from the MSBOOST trial.
    Mult Scler. 2025;31:174-183.
    >> Share

  116. CACCIAGUERRA L, Storelli L, Pagani E, Preziosa P, et al
    Use of brain MRI and gene expression atlases to reconstruct the pathophysiology of autoimmune neurological disorders: The proof-of-concept of NMOSD.
    Mult Scler. 2025;31:140-158.
    >> Share

  117. CORBOY JR, Fox RJ, Cutter G, Engebretson E, et al
    DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
    Mult Scler. 2025;31:159-173.
    >> Share

  118. LEBRUN-FRENAY C, Kerbrat S, Okuda DT, Landes-Chateau C, et al
    Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome.
    Mult Scler. 2025;31:184-196.
    >> Share

  119. PATEL AD, Connors A, Esch ME
    Ofatumumab-associated colitis: A case report.
    Mult Scler. 2025;31:242-245.
    >> Share

    January 2025
  120. MARTIRE MS, Moiola L, Maggi P, Borrelli S, et al
    Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients.
    Mult Scler. 2025 Jan 31:13524585251314358. doi: 10.1177/13524585251314358.
    >> Share

  121. ACHIRON A, Warszawer Y, Nissan Y, Kerpel A, et al
    Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
    Mult Scler. 2025 Jan 27:13524585251313749. doi: 10.1177/13524585251313749.
    >> Share

  122. DE ANGELIS F, Ammoscato F, Parker RA, Plantone D, et al
    Neurofilament heavy chain in secondary progressive multiple sclerosis.
    Mult Scler. 2025 Jan 22:13524585241311212. doi: 10.1177/13524585241311212.
    >> Share

  123. VARLEY JA, Davies NW
    Opportunistic enteroviral infections in MS patients treated with anti-CD20 therapies.
    Mult Scler. 2025 Jan 20:13524585241310395. doi: 10.1177/13524585241310395.
    >> Share

  124. YILMAZER C, D'haeseleer M, Soler B, Van Wijmeersch B, et al
    Assessing pain in multiple sclerosis: Test-retest reliability of patient-reported outcome measures and accuracy of screening tools.
    Mult Scler. 2025 Jan 16:13524585241310139. doi: 10.1177/13524585241310139.
    >> Share

  125. DEL CANTO A, Carcamo C, Garcia L, Aylwin E, et al
    Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
    Mult Scler. 2025 Jan 6:13524585241309835. doi: 10.1177/13524585241309835.
    >> Share

  126. WITT L, Dost-Kovalsky K, Friedmann N, Bast N, et al
    Ofatumumab-exposed breastfeeding in multiple sclerosis patients.
    Mult Scler. 2025 Jan 6:13524585241307165. doi: 10.1177/13524585241307165.
    >> Share

  127. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.
    Mult Scler. 2025 Jan 3:13524585241310104. doi: 10.1177/13524585241310104.
    >> Share

  128. SIMANI L, Tozlu C, Lee S, Dworkin J, et al
    Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.
    Mult Scler. 2025 Jan 3:13524585241303491. doi: 10.1177/13524585241303491.
    >> Share

  129. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
    Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
    Mult Scler. 2025;31:44-58.
    >> Share

  130. MANISCALCO GT, Dinoto A, Foglia MC, Di Battista ME, et al
    Epstein-Barr virus infection in patients with MOGAD.
    Mult Scler. 2025;31:117-120.
    >> Share

  131. CARNERO CONTENTTI E, Rotstein D, Okuda DT, Paul F, et al
    How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder.
    Mult Scler. 2025;31:8-22.
    >> Share

    December 2024
  132. MAGGI G, Altieri M, Risi M, Rippa V, et al
    Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Dec 27:13524585241302167. doi: 10.1177/13524585241302167.
    >> Share

  133. BRIGGS FB, Conway DS, Hersh CM, Fitzgerald KC, et al
    The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans.
    Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976.
    >> Share

  134. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Dec 20:13524585241304356. doi: 10.1177/13524585241304356.
    >> Share

  135. MALLUCCI G, Zimmer A, Sfikas N, Cerda-Fuertes N, et al
    Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
    Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966.
    >> Share

  136. CORREALE J, Marrodan M
    Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.
    Mult Scler. 2024 Dec 18:13524585241305956. doi: 10.1177/13524585241305956.
    >> Share

  137. NYLANDER A, Sisodia N, Henderson K, Wijangco J, et al
    From "invisible" to "audible": Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis.
    Mult Scler. 2024 Dec 17:13524585241303855. doi: 10.1177/13524585241303855.
    >> Share

  138. VAN DAM M, Rottgering JG, Nauta IM, de Jong BA, et al
    Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.
    Mult Scler. 2024 Dec 9:13524585241302173. doi: 10.1177/13524585241302173.
    >> Share

  139. KRYSKO KM
    Considerations for family planning in adolescent and young adults with multiple sclerosis.
    Mult Scler. 2024 Dec 7:13524585241303481. doi: 10.1177/13524585241303481.
    >> Share

  140. CHANG G, Stoney S, Narula S
    Pregnancy outcomes in adolescent and young adult patients with multiple sclerosis: A case series.
    Mult Scler. 2024 Dec 7:13524585241303490. doi: 10.1177/13524585241303490.
    >> Share

  141. FRAMKE E, Sellebjerg F, Kant M, Stilund M, et al
    Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
    Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715.
    >> Share

  142. CARVAJAL R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, et al
    Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
    Mult Scler. 2024;30:1788-1801.
    >> Share

  143. KEVER A, Heuer LB, Simani L, Leavitt VM, et al
    Development and initial validation of the Cognitive Change Scale (CCS).
    Mult Scler. 2024;30:1815-1824.
    >> Share

  144. JIANG X, McGinley M, Johnston J, Alberts J, et al
    A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis.
    Mult Scler. 2024 Dec 1:13524585241301854. doi: 10.1177/13524585241301854.
    >> Share

  145. CHITNIS T, Arnold DL, Quartier P, Chirieac M, et al
    Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study.
    Mult Scler. 2024 Dec 1:13524585241295554. doi: 10.1177/13524585241295554.
    >> Share

  146. PORTACCIO E
    Toward a holistic approach to multiple sclerosis: The role of social determinants of health.
    Mult Scler. 2024 Dec 1:13524585241302684. doi: 10.1177/13524585241302684.
    >> Share

  147. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
    Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
    Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276.
    >> Share

  148. GAITAN MI, Marquez RV, Ayerbe J, Reich DS, et al
    Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.
    Mult Scler. 2024;30.
    >> Share

  149. MOTL RW
    Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs.
    Mult Scler. 2024;30.
    >> Share

  150. PILUTTI LA, Donkers SJ
    Exercise as a Therapeutic Intervention in Multiple Sclerosis.
    Mult Scler. 2024;30.
    >> Share

  151. MCGINLEY MP
    Improving Access to MS Care Through Technology.
    Mult Scler. 2024;30.
    >> Share

  152. BERGSLAND N, Dwyer MG, Zivadinov R
    Imaging the Choroid Plexus.
    Mult Scler. 2024;30.
    >> Share

  153. LANGER-GOULD A
    Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No.
    Mult Scler. 2024;30.
    >> Share

  154. KOCH MW, Camara-Lemarroy C, Strijbis E, Mostert J, et al
    Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.
    Mult Scler. 2024;30.
    >> Share

  155. ONTANEDA D, Miron VE
    Breaking Barriers in Multiple Sclerosis.
    Mult Scler. 2024;30.
    >> Share

    November 2024
  156. LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al
    Association between education level and disability progression in patients with multiple sclerosis in France.
    Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274.
    >> Share

  157. KALAITZIDIS G, Ezzedin O, Bacchetti A, Moussa H, et al
    Homonymous hemi-macular atrophy in multiple sclerosis.
    Mult Scler. 2024 Nov 23:13524585241297816. doi: 10.1177/13524585241297816.
    >> Share

  158. GANS A, Verrengia EP, Ricchiuti E, Leva S, et al
    Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.
    Mult Scler. 2024 Nov 21:13524585241295677. doi: 10.1177/13524585241295677.
    >> Share

  159. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
    Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study.
    Mult Scler. 2024 Nov 14:13524585241297003. doi: 10.1177/13524585241297003.
    >> Share

  160. MAGGI P, Absinta M
    Emerging MRI biomarkers for the diagnosis of multiple sclerosis.
    Mult Scler. 2024 Nov 7:13524585241293579. doi: 10.1177/13524585241293579.
    >> Share

  161. HOFFMAN EM, Brown L, Jolliffe E, Sechi E, et al
    McArdle sign and neck flexion-induced change in central motor conduction in multiple sclerosis.
    Mult Scler. 2024 Nov 6:13524585241295868. doi: 10.1177/13524585241295868.
    >> Share

  162. WITT L, Haben S, Dost-Kovalsky K, Friedmann N, et al
    Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.
    Mult Scler. 2024 Nov 6:13524585241293363. doi: 10.1177/13524585241293363.
    >> Share

  163. HOCHSTETLER A, Lehtinen MK
    Choroid plexus as a mediator of CNS inflammation in multiple sclerosis.
    Mult Scler. 2024 Nov 6:13524585241292974. doi: 10.1177/13524585241292974.
    >> Share

  164. JIANG Y, Cesta CE, Liu Q, Kingwell E, et al
    Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis.
    Mult Scler. 2024 Nov 6:13524585241292802. doi: 10.1177/13524585241292802.
    >> Share

  165. TOOROP AA, Wessels MH, Boonkamp L, Gelissen LM, et al
    Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
    Mult Scler. 2024 Nov 4:13524585241293940. doi: 10.1177/13524585241293940.
    >> Share

  166. HSU S, Balan A, Bove R
    Topical review: Lactation and use of DMTs in women with MS.
    Mult Scler. 2024;30:1578-1591.
    >> Share

  167. NOVI G, Sbragia E, Benedetti L, Schenone A, et al
    Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.
    Mult Scler. 2024;30:1692-1696.
    >> Share

    October 2024
  168. YOUNG CA, Rog DJ, Sharrack B, Tanasescu R, et al
    Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).
    Mult Scler. 2024 Oct 30:13524585241288393. doi: 10.1177/13524585241288393.
    >> Share

  169. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    Phenotyping in vivo chronic inflammation in multiple sclerosis by combined (11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging.
    Mult Scler. 2024 Oct 22:13524585241284157. doi: 10.1177/13524585241284157.
    >> Share


  170. Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI: 10.1177/13524585241260564.
    Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986.
    >> Share

  171. PALLADINO R, Chataway J, Mathew M, Majeed A, et al
    Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.
    Mult Scler. 2024 Oct 17:13524585241287388. doi: 10.1177/13524585241287388.
    >> Share

  172. DE NADAI AS, Zamora RJ, Finch A, Miller DM, et al
    Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample.
    Mult Scler. 2024 Oct 17:13524585241282763. doi: 10.1177/13524585241282763.
    >> Share

  173. VAN LIEROP ZY, Wessels MH, Lekranty WM, Moraal B, et al
    Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
    Mult Scler. 2024 Oct 17:13524585241277044. doi: 10.1177/13524585241277044.
    >> Share

  174. VLAD B, Neidhart S, Hilty M, Asplund Hogelin K, et al
    Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.
    Mult Scler. 2024 Oct 8:13524585241279645. doi: 10.1177/13524585241279645.
    >> Share

  175. AMEZCUA L, Hamilton RH, Ciccarelli O
    The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce.
    Mult Scler. 2024 Oct 8:13524585241286988. doi: 10.1177/13524585241286988.
    >> Share

  176. VERCELLINO M, Marasciulo S, Ricotti E, Rolando A, et al
    Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
    Mult Scler. 2024 Oct 7:13524585241284846. doi: 10.1177/13524585241284846.
    >> Share

  177. LEE S, Marrie RA, Fadda G, Freedman MS, et al
    Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack.
    Mult Scler. 2024;30.
    >> Share

    September 2024
  178. NESBITT C, Van Der Walt A, Butzkueven H, Devitt B, et al
    Multiple sclerosis and cancer: Navigating a dual diagnosis.
    Mult Scler. 2024 Sep 30:13524585241274523. doi: 10.1177/13524585241274523.
    >> Share

  179. BAYOUMI A, Hasan KM, Thomas JA, Yazdani A, et al
    Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.
    Mult Scler. 2024 Sep 29:13524585241280842. doi: 10.1177/13524585241280842.
    >> Share

  180. OCAMPO A, Hatami F, Cuklina J, Graham G, et al
    Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.
    Mult Scler. 2024 Sep 28:13524585241275471. doi: 10.1177/13524585241275471.
    >> Share

  181. INOJOSA H, Voigt I, Wenk J, Ferber D, et al
    Integrating large language models in care, research, and education in multiple sclerosis management.
    Mult Scler. 2024 Sep 23:13524585241277376. doi: 10.1177/13524585241277376.
    >> Share

  182. JACOBS BM, Schalk L, Tregaskis-Daniels E, Tank P, et al
    The relationship between ethnicity and multiple sclerosis characteristics in the United Kingdom: A UK MS Register study.
    Mult Scler. 2024 Sep 20:13524585241277018. doi: 10.1177/13524585241277018.
    >> Share

  183. O'DONNELL E, Schuette A, Waltz M, Aaen G, et al
    Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis.
    Mult Scler. 2024 Sep 17:13524585241274580. doi: 10.1177/13524585241274580.
    >> Share

  184. PILLONI G, Lustberg M, Malik M, Feinberg C, et al
    Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial.
    Mult Scler. 2024 Sep 13:13524585241275013. doi: 10.1177/13524585241275013.
    >> Share

  185. LANDI D, Bartolomeo S, Bovis F, Amato MP, et al
    Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy.
    Mult Scler. 2024 Sep 12:13524585241274600. doi: 10.1177/13524585241274600.
    >> Share

  186. HOLTZER R, Foley FW, Motl RW, Wagshul ME, et al
    Brain hemodynamic responses and fall prediction in older adults with multiple sclerosis.
    Mult Scler. 2024 Sep 11:13524585241277400. doi: 10.1177/13524585241277400.
    >> Share

  187. PIEDRABUENA MA, Correale J, Farez MF, Rodriguez Murua S, et al
    Telomere length as a biomarker in multiple sclerosis.
    Mult Scler. 2024 Sep 9:13524585241273054. doi: 10.1177/13524585241273054.
    >> Share

  188. LUNEMANN JD, Sao Aviles A, Tintore M, Midaglia L, et al
    Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset.
    Mult Scler. 2024 Sep 9:13524585241274571. doi: 10.1177/13524585241274571.
    >> Share

  189. ZURRER WE, Cannon AE, Ilchenko D, Gaitan MI, et al
    Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2024 Sep 8:13524585241274527. doi: 10.1177/13524585241274527.
    >> Share

  190. SARTHOU A, Chretien P, Giorgi L, Chiron A, et al
    The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis.
    Mult Scler. 2024 Sep 8:13524585241274034. doi: 10.1177/13524585241274034.
    >> Share

  191. COERVER EM, Kacar S, Ciccarelli O, Sormani MP, et al
    Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.
    Mult Scler. 2024 Sep 8:13524585241272938. doi: 10.1177/13524585241272938.
    >> Share

  192. BRIGGS FB, Gunzler DD, Miller DM, Ontaneda D, et al
    Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure.
    Mult Scler. 2024 Sep 5:13524585241274607. doi: 10.1177/13524585241274607.
    >> Share

  193. PETRACCA M, Ruggieri S, Nistri R, Tomasso I, et al
    Brain reserve and timing of clinical onset in multiple sclerosis.
    Mult Scler. 2024 Sep 5:13524585241272046. doi: 10.1177/13524585241272046.
    >> Share

  194. TOLJAN K, Daboul L, Raza P, Martin ML, et al
    Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.
    Mult Scler. 2024 Sep 5:13524585241271988. doi: 10.1177/13524585241271988.
    >> Share

  195. LANDES-CHATEAU C, Ricigliano VA, Mondot L, Thouvenot E, et al
    Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.
    Mult Scler. 2024;30:1278-1289.
    >> Share

  196. CHICO-GARCIA JL, Sainz Amo R, Monreal E, Sainz de la Maza S, et al
    Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.
    Mult Scler. 2024;30:1341-1349.
    >> Share

  197. ROTSTEIN DL, Freedman MS, Konig A, Lee L, et al
    Investigation of health care use and a possible prodrome before the first attack in NMOSD and MOGAD.
    Mult Scler. 2024;30:1331-1340.
    >> Share

  198. COBO-CALVO A, Tintore M
    Prioritizing global strategies to cure MS.
    Mult Scler. 2024;30:1239-1241.
    >> Share

  199. ABBATEMARCO JR, Aboseif A, Swetlik C, Widmar J, et al
    Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder.
    Mult Scler. 2024;30:1322-1330.
    >> Share

  200. KRUPP L, O'Neill KA
    Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
    Mult Scler. 2024;30:1252-1254.
    >> Share

  201. KLEIN M
    Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
    Mult Scler. 2024;30:1254-1256.
    >> Share

    August 2024
  202. BEBO BF JR, Banwell BL, Whitacre CC, Coetzee T, et al
    The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
    Mult Scler. 2024 Aug 30:13524585241266483. doi: 10.1177/13524585241266483.
    >> Share

  203. ZICCARDI S, Guandalini M, Fuchs TA, Calabrese M, et al
    The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now.
    Mult Scler. 2024 Aug 28:13524585241264476. doi: 10.1177/13524585241264476.
    >> Share

  204. FUCHS TA, Schoonheim MM, Zivadinov R, Dwyer MG, et al
    Cognitive progression independent of relapse in multiple sclerosis.
    Mult Scler. 2024 Aug 28:13524585241256540. doi: 10.1177/13524585241256540.
    >> Share

  205. TUR C, Portaccio E
    Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline.
    Mult Scler. 2024 Aug 28:13524585241273037. doi: 10.1177/13524585241273037.
    >> Share

  206. RIVERO-DE-AGUILAR A, Perez-Rios M, Mascarenas-Garcia M, Ruano-Ravina A, et al
    Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals.
    Mult Scler. 2024 Aug 27:13524585241273089. doi: 10.1177/13524585241273089.
    >> Share

  207. CICCARESE G, Zanghi A, Herzum A, Fidanzi C, et al
    Acute urticaria following ofatumumab injection for multiple sclerosis.
    Mult Scler. 2024 Aug 26:13524585241273084. doi: 10.1177/13524585241273084.
    >> Share

  208. HARROUD A, Sawcer SJ, Baranzini SE
    Genetics of multiple sclerosis severity: The importance of statistical power in replication studies.
    Mult Scler. 2024 Aug 14:13524585241264472. doi: 10.1177/13524585241264472.
    >> Share

  209. MONTOBBIO N, Carmisciano L, Signori A, Ponzano M, et al
    Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.
    Mult Scler. 2024 Aug 14:13524585241243157. doi: 10.1177/13524585241243157.
    >> Share

  210. LAPUCCI C, Frau J, Cocco E, Coghe G, et al
    Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
    Mult Scler. 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.
    >> Share

  211. KALINCIK T
    The era of harmonised disability outcomes in multiple sclerosis.
    Mult Scler. 2024 Aug 14:13524585241266517. doi: 10.1177/13524585241266517.
    >> Share

  212. CAMPAGNA MP, Lechner-Scott J, Taylor BV, Havrdova EK, et al
    Re: Genetics of multiple sclerosis severity: The importance of statistical power in replication studies and Re: From discovery to replication: Power and definitions matter for multiple sclerosis severity.
    Mult Scler. 2024 Aug 14:13524585241264469. doi: 10.1177/13524585241264469.
    >> Share

  213. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
    Mult Scler. 2024 Aug 7:13524585241267257. doi: 10.1177/13524585241267257.
    >> Share

  214. CAMPBELL JA, Simpson-Yap S, Taylor BV, van der Mei I, et al
    Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021.
    Mult Scler. 2024 Aug 5:13524585241265890. doi: 10.1177/13524585241265890.
    >> Share

  215. CAMERON MH, Hildebrand A, Hugos C, Wooliscroft L, et al
    A walking aid selection, training, and education program (ADSTEP) to prevent falls in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2024 Aug 5:13524585241265031. doi: 10.1177/13524585241265031.
    >> Share

  216. DVORAK E, Levy S, Anderson JR, Sumowski JF, et al
    Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis.
    Mult Scler. 2024 Aug 5:13524585241259648. doi: 10.1177/13524585241259648.
    >> Share

  217. ROOS I, Sharmin S, Malpas C, Ozakbas S, et al
    Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211.
    >> Share

  218. VOSKUHL R
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Yes.
    Mult Scler. 2024;30:1107-1109.
    >> Share

  219. ZHANG Q, Noyce AJ, Robson J, Giovannoni G, et al
    No association between oral contraceptive exposure and subsequent MS: A population-based nested case-control study in primary care.
    Mult Scler. 2024;30:1221-1226.
    >> Share

  220. CHEEMA S, Matharu M
    Facial pain in MS: When to think of trigeminal autonomic cephalalgia.
    Mult Scler. 2024;30:1230-1231.
    >> Share

    July 2024
  221. BEBO B, Coetzee T, Gray E, Helme A, et al
    The first global landscape analysis of multiple sclerosis research funding.
    Mult Scler. 2024 Jul 31:13524585241265961. doi: 10.1177/13524585241265961.
    >> Share

  222. PROSPERINI L, Ruggieri S, Haggiag S, Tortorella C, et al
    Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.
    Mult Scler. 2024 Jul 31:13524585241266180. doi: 10.1177/13524585241266180.
    >> Share

  223. ROMOZZI M, Vollono C, Calabresi P, Iorio R, et al
    Epilepsia Partialis Continua as a manifestation of aquaporin-4 autoimmunity.
    Mult Scler. 2024 Jul 30:13524585241261535. doi: 10.1177/13524585241261535.
    >> Share

  224. CARNERO CONTENTTI E
    Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and meningoencephalitis.
    Mult Scler. 2024 Jul 30:13524585241261545. doi: 10.1177/13524585241261545.
    >> Share

  225. SIDHU NK, Proudfoot H, Adan HM, Fawson S, et al
    Diversity and inclusion in behavioural intervention trials in multiple sclerosis: A commentary.
    Mult Scler. 2024 Jul 26:13524585241248279. doi: 10.1177/13524585241248279.
    >> Share

  226. STRIDH P, Huang J, Kockum I
    From discovery to replication: Power and definitions matter for multiple sclerosis severity.
    Mult Scler. 2024 Jul 26:13524585241265021. doi: 10.1177/13524585241265021.
    >> Share

  227. MOHAN SD, Peterson S, Brenton JN, Carmichael SL, et al
    Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis.
    Mult Scler. 2024;30:1056-1065.
    >> Share

  228. ZEINEDDINE M, Al-Roughani R, Farouk Ahmed S, Khoury S, et al
    Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Mult Scler. 2024;30:1026-1035.
    >> Share

  229. UZAWA A, Mori M, Masuda H, Muto M, et al
    Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2024;30:977-982.
    >> Share

  230. DE JONG DJ, Strijbis EM, Killestein J
    Information from ecological momentary assessments lead to over-medicalization: Commentary.
    Mult Scler. 2024;30:972-973.
    >> Share

  231. PREZIOSA P, Rocca MA, Filippi M
    Information from ecological momentary assessments leads to over-medicalization: No.
    Mult Scler. 2024;30:970-972.
    >> Share

  232. HOGESTOL EA, Berg-Hansen P
    Information from ecological momentary assessments lead to over-medicalization: Yes.
    Mult Scler. 2024;30:968-969.
    >> Share

  233. LEVIT E, Ren Z, Gonzenbach V, Azevedo CJ, et al
    Choroid plexus volume differentiates MS from its mimics.
    Mult Scler. 2024;30:1072-1076.
    >> Share

  234. MEALLI F, Mattei A, Mariottini A, Massacesi L, et al
    Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
    Mult Scler. 2024;30:1077-1080.
    >> Share

  235. COBAN H
    Tick-borne illnesses in patients treated with B-cell depleting agents: Considerations for neurologists.
    Mult Scler. 2024;30:1084-1085.
    >> Share

  236. MCMURRAN CE, Mukherjee T, Brown JWL, Coles AJ, et al
    Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
    Mult Scler. 2024;30:1066-1071.
    >> Share

    June 2024
  237. MOROZUMI T, Preziosa P, Meani A, Pessina G, et al
    Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis.
    Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145.
    >> Share

  238. MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al
    Impact of multiple sclerosis comorbidities on quality of life and job activity.
    Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550.
    >> Share

  239. SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al
    Konectom cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
    Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650.
    >> Share

  240. MAGYARI M
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No.
    Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987.
    >> Share

  241. PETHERAM K, Dobson R
    All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: Commentary.
    Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989.
    >> Share

  242. CONTE WL
    Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for research and action.
    Mult Scler. 2024 Jun 19:13524585241263281. doi: 10.1177/13524585241263281.
    >> Share

  243. MORROW SA, Hancock L
    Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
    Mult Scler. 2024 Jun 16:13524585241261200. doi: 10.1177/13524585241261200.
    >> Share

  244. BALSHI A, Manning N, Dempsey J, Kumbar S, et al
    Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab.
    Mult Scler. 2024 Jun 16:13524585241260537. doi: 10.1177/13524585241260537.
    >> Share

  245. KOLSCHE T, Willison AG, Meuth SG, Pawlitzki M, et al
    Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
    Mult Scler. 2024 Jun 15:13524585241260564. doi: 10.1177/13524585241260564.
    >> Share

  246. DALLA COSTA G, Leocani L, Pisa M, Croese T, et al
    Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.
    Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977.
    >> Share

  247. KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al
    Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.
    Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968.
    >> Share

  248. SMETS I, Versteegh M, Huygens S, Wokke B, et al
    Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
    Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692.
    >> Share

  249. NOVA A, Di Caprio G, Bernardinelli L, Fazia T, et al
    Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study.
    Mult Scler. 2024 Jun 7:13524585241257205. doi: 10.1177/13524585241257205.
    >> Share

  250. BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al
    Enlarged perivascular spaces are associated with brain microangiopathy and aging in multiple sclerosis.
    Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881.
    >> Share

  251. PONZANO M, Signori A, Bellavia A, Carbone A, et al
    Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review.
    Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283.
    >> Share

  252. FOSTER MA, Prados F, Collorone S, Kanber B, et al
    Improving explanation of motor disability with diffusion-based graph metrics at onset of the first demyelinating event.
    Mult Scler. 2024;30:800-811.
    >> Share

  253. MONTOBBIO N, Bovis F, Signori A, Ponzano M, et al
    Therapeutic lag: Is treatment effect delayed in progressive MS?
    Mult Scler. 2024;30:843-846.
    >> Share

  254. PFEUFFER S
    Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
    Mult Scler. 2024;30:897-898.
    >> Share

    May 2024
  255. AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
    Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
    >> Share

  256. MENG D, Sacco R, Disanto G, Widmer F, et al
    Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
    >> Share

  257. LEBRUN-FRENAY C, Okuda DT
    Time to move past typical syndromes in the diagnosis of multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519.
    >> Share

  258. WICKLEIN R, Kreitner L, Wild A, Aly L, et al
    Retinal small vessel pathology is associated with disease burden in multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775.
    >> Share

  259. NAIZER H, Wozny J, Krause TM, Huson E, et al
    Trends in central nervous system-active polypharmacy among people with multiple sclerosis.
    Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986.
    >> Share

  260. HEWARD KD, Roy-Hewitson C, Solomon AJ
    Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.
    Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513.
    >> Share

  261. COLLORONE S, Coll L, Lorenzi M, Llado X, et al
    Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis.
    Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422.
    >> Share

  262. DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al
    The association of comorbidities with sleep quality among Australians with multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal Study.
    Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278.
    >> Share

  263. ANDERSEN ML, Jolving LR, Iachina M, Stenager E, et al
    Children born preterm or small for gestational age to mothers with multiple sclerosis: Do these children have an increased risk of infections in early life?
    Mult Scler. 2024 May 8:13524585241249077. doi: 10.1177/13524585241249077.
    >> Share

  264. PROSPERINI L, Haggiag S
    Late-onset multiple sclerosis from a different angle.
    Mult Scler. 2024 May 8:13524585241249901. doi: 10.1177/13524585241249901.
    >> Share

  265. PORTACCIO E, Grossi P, Bellomi F, Bianchi V, et al
    Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis.
    Mult Scler. 2024 May 8:13524585241249084. doi: 10.1177/13524585241249084.
    >> Share

    April 2024
  266. FEINSTEIN A
    Depression is a core symptom of multiple sclerosis.
    Mult Scler. 2024 Apr 30:13524585241245637. doi: 10.1177/13524585241245637.
    >> Share

  267. HANCOCK LM
    Depression is a core symptom of multiple sclerosis: Yes.
    Mult Scler. 2024 Apr 30:13524585241249564. doi: 10.1177/13524585241249564.
    >> Share

  268. LEAVITT VM
    Depression is a core symptom of multiple sclerosis: NO.
    Mult Scler. 2024 Apr 30:13524585241245653. doi: 10.1177/13524585241245653.
    >> Share

  269. MANUEL AM, Gottlieb A, Freeman L, Zhao Z, et al
    Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.
    Mult Scler. 2024 Apr 25:13524585241240398. doi: 10.1177/13524585241240398.
    >> Share

  270. BIANCHI A, Cortese R, Prados F, Tur C, et al
    Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.
    Mult Scler. 2024 Apr 22:13524585241240420. doi: 10.1177/13524585241240420.
    >> Share

  271. NOVAK F, Bajwa HM, Ostergaard K, Berg JM, et al
    Extended interval dosing with ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296.
    >> Share

  272. OKUDA DT, Lebrun-Frenay C
    Radiologically isolated syndrome in the spectrum of multiple sclerosis.
    Mult Scler. 2024 Apr 15:13524585241245306. doi: 10.1177/13524585241245306.
    >> Share

  273. CHITNIS T, Banwell B, Kappos L, Arnold DL, et al
    Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Mult Scler. 2024 Apr 15:13524585241242050. doi: 10.1177/13524585241242050.
    >> Share

  274. HEMOND CC, Solomon AJ
    Multiple sclerosis can be diagnosed solely with dissemination in space: No.
    Mult Scler. 2024 Apr 14:13524585241245297. doi: 10.1177/13524585241245297.
    >> Share

  275. MCGINLEY MP, Cohen JA
    Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary.
    Mult Scler. 2024 Apr 14:13524585241245319. doi: 10.1177/13524585241245319.
    >> Share

  276. TOOSY AT, Barkhof F
    Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.
    Mult Scler. 2024 Apr 14:13524585241245313. doi: 10.1177/13524585241245313.
    >> Share

  277. OZTURK B, Taskiran E, Demir S, Tuncer MA, et al
    Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study.
    Mult Scler. 2024 Apr 14:13524585241245318. doi: 10.1177/13524585241245318.
    >> Share

  278. SCHNEIDER M, Kramer J, Banks A, Moses H, et al
    New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
    Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027.
    >> Share

  279. MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al
    Neurofilament in clinical practice: Is the multiple sclerosis community ready?
    Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536.
    >> Share

  280. KWON S, Han KD, Jung JH, Cho EB, et al
    Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093.
    >> Share

  281. ALOISI F, Salvetti M
    EBV infection drives MS pathology: Yes.
    Mult Scler. 2024;30.
    >> Share

  282. CORTESE M, Ascherio A
    EBV infection drives MS pathology: Commentary.
    Mult Scler. 2024;30.
    >> Share

  283. 'T HART BA, van Luijn MM
    EBV infection drives MS pathology: No.
    Mult Scler. 2024;30.
    >> Share

  284. TUR C, Battiston M, Yiannakas MC, Collorone S, et al
    What contributes to disability in progressive MS? A brain and cervical cord-matched quantitative MRI study.
    Mult Scler. 2024;30.
    >> Share

  285. REEVES JA, Mohebbi M, Wicks T, Salman F, et al
    Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.
    Mult Scler. 2024;30.
    >> Share

  286. KLISTORNER S, Barnett MH, Wang C, Parratt J, et al
    Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients.
    Mult Scler. 2024;30.
    >> Share

  287. SBRAGIA E, Boffa G, Varaldo R, Raiola AM, et al
    An aggressive form of MOGAD treated with aHSCT: A case report.
    Mult Scler. 2024;30.
    >> Share

    March 2024
  288. PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al
    Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
    Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653.
    >> Share

  289. SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
    Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis.
    Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
    >> Share

  290. SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
    Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
    Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
    >> Share

  291. MAILLART E, Redolfi S, Louapre C, Houot M, et al
    Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort.
    Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
    >> Share

  292. CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
    No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
    Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
    >> Share

  293. HJALGRIM H, Rostgaard K
    Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
    Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
    >> Share

  294. GOLDACRE R
    Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
    Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
    >> Share

  295. JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
    Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
    >> Share

  296. NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
    Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
    >> Share

  297. EHLING R, Seebacher B, Brenneis C
    Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
    >> Share

  298. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
    Expert opinion on the use of contraception in people with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
    >> Share

  299. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
    >> Share

  300. KUBICKI K, Stefoski D
    Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
    Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
    >> Share

  301. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
    >> Share

  302. GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
    SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
    Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
    >> Share

  303. ROCCHI C, Forcadela M, Kelly P, Linaker S, et al
    The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
    Mult Scler. 2024;30:345-356.
    >> Share

    February 2024
  304. AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
    Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
    Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
    >> Share

  305. KARI S, Bucciarelli F, Angles T, Oster AC, et al
    Increased levels of circulating soluble CD226 in multiple sclerosis.
    Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
    >> Share

  306. HEESEN C, Luhmann D
    Reply: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
    >> Share

  307. LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
    Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
    >> Share

  308. NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
    BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
    Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
    >> Share

  309. MILLER AE
    Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
    Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
    >> Share

  310. KRIEGER SC, Sinks S, Huang F, Steverson J, et al
    The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
    Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
    >> Share

  311. BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
    T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
    >> Share

  312. EMMA C, Vesela P, Kay P, Huseyin H, et al
    Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
    >> Share

  313. ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
    Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
    >> Share

  314. JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
    >> Share

  315. ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
    2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
    >> Share

  316. ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
    Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
    Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
    >> Share

  317. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
    A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
    Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
    >> Share

  318. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
    Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
    >> Share

  319. PATEL S, Rafferty S, Aquino L, Chadha S, et al
    VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
    Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
    >> Share

  320. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
    Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
    >> Share

  321. MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
    Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
    Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
    >> Share

  322. BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
    Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
    Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
    >> Share

  323. ZIAEI A, Solomon O, Casper TC, Waltz M, et al
    Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
    Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
    >> Share

  324. GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
    Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
    >> Share

  325. MCGINLEY MP, Manouchehrinia A
    The landscape of multiple sclerosis registries: Strengths and limitations.
    Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
    >> Share

  326. VUKUSIC S, Bourre B, Casey R, Deiva K, et al
    The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
    Mult Scler. 2024;30:216-226.
    >> Share

  327. GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
    Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
    Mult Scler. 2024;30:238-246.
    >> Share

  328. SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
    Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
    Mult Scler. 2024;30:156-165.
    >> Share

  329. GONZALEZ CALDITO N, Graham EL, Grebenciucova E
    Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
    Mult Scler. 2024;30:272-274.
    >> Share

  330. LANGDON D
    Neuropsychological assessment in MS is outdated and in need for innovation: NO.
    Mult Scler. 2024;30:152-153.
    >> Share

    January 2024
  331. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
    Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
    >> Share

  332. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
    Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
    >> Share

  333. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
    White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
    Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
    >> Share

  334. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
    Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
    Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
    >> Share

  335. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
    Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
    >> Share

  336. JEANTIN L, Januel E, Labauge P, Maillart E, et al
    COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
    >> Share

  337. TENI FS, Machado A, Fink K, Gyllensten H, et al
    Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
    >> Share

  338. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
    Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
    Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
    >> Share

  339. TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
    Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
    >> Share

  340. DAS J, Rog DJ, Middleton R, Rodgers JW, et al
    University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
    Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
    >> Share

  341. PORTACCIO E, Iaffaldano P
    Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
    Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
    >> Share

  342. FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
    Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
    Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
    >> Share

  343. MOTYL J
    Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
    Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
    >> Share

  344. MORROW SA
    Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
    Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
    >> Share

  345. VENET M, Lepine A, Maarouf A, Biotti D, et al
    Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
    Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
    >> Share

  346. WEINSHENKER BG
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary.
    Mult Scler. 2024;30:23-24.
    >> Share

  347. CARNERO CONTENTTI E, Wingerchuk DM
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.
    Mult Scler. 2024;30:19-21.
    >> Share

  348. MARIGNIER R, Cree BA
    MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No.
    Mult Scler. 2024;30:21-23.
    >> Share

  349. VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
    The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
    Mult Scler. 2024;30:121-130.
    >> Share

  350. HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
    Stretching is not essential for managing MS spasticity: A randomized controlled trial.
    Mult Scler. 2024;30:89-102.
    >> Share

  351. DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
    Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
    Mult Scler. 2024;30:71-79.
    >> Share

  352. GUO RY, Wang WY, Huang JY, Jia Z, et al
    Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors.
    Mult Scler. 2024;30:7-15.
    >> Share

  353. WRIGHT SL, Thompson AJ
    Managing patients with late-onset neutropenia during treatment with ocrelizumab.
    Mult Scler. 2024;30:134.
    >> Share

  354. KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
    Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
    Mult Scler. 2024;30:113-120.
    >> Share

    December 2023
  355. PARCIAK T, Geys L, Helme A, van der Mei I, et al
    Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
    Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
    >> Share

  356. DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
    A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
    Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
    >> Share

  357. NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
    Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
    Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
    >> Share

  358. TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
    Clinical and radiological correlates of apathy in multiple sclerosis.
    Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
    >> Share

  359. DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
    A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
    Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
    >> Share

  360. DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
    A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
    Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
    >> Share

  361. BRUCE JM, Cozart JS, Shook RP, Befort C, et al
    Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
    Mult Scler. 2023;29:1860-1871.
    >> Share

  362. SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
    Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2023;29:1736-1747.
    >> Share

  363. LUBLIN FD
    Worsening MS-A reappraisal of how we characterize the MS disease course.
    Mult Scler. 2023;29:1699-1700.
    >> Share

  364. SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
    Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
    Mult Scler. 2023;29:1721-1735.
    >> Share

  365. PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
    Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Mult Scler. 2023;29:1849-1859.
    >> Share

  366. MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
    Detecting isolated cognitive relapses in persons with MS.
    Mult Scler. 2023;29:1786-1794.
    >> Share

  367. ENGELS D, Havla J, Forderreuther S, Kumpfel T, et al
    Therapy challenges for NMOSD in a patient with HIV.
    Mult Scler. 2023;29:1872-1875.
    >> Share

    November 2023
  368. MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
    Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
    Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
    >> Share

  369. ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
    The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
    Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
    >> Share

  370. MONTEIRO IR, Moccia M
    Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
    Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
    >> Share

  371. CASTANO-AMORES C, Nieto-Gomez P
    The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
    Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
    >> Share

  372. LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
    Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
    >> Share

  373. NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
    Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
    Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
    >> Share

  374. BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
    >> Share

  375. NICHOLSON S, Russo AW, Brewer K, Bien H, et al
    The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
    >> Share

  376. BOU RJEILY N, Fitzgerald KC, Mowry EM
    Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
    >> Share

  377. AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
    Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
    >> Share

  378. VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
    Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
    Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
    >> Share

  379. ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
    Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
    >> Share

  380. FEINSTEIN A
    The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
    Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
    >> Share

  381. CHASE E, Chen V, Martin K, Lane M, et al
    A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
    Mult Scler. 2023;29:1659-1675.
    >> Share

  382. WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
    Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
    Mult Scler. 2023;29:1646-1658.
    >> Share

  383. WISHART M, Everest MR, Morrow SA, Rose J, et al
    Establishing the consistency of a voice recognition symbol digit modalities test analogue.
    Mult Scler. 2023;29:1676-1679.
    >> Share

  384. BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
    Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
    Mult Scler. 2023;29:1688-1692.
    >> Share

    October 2023
  385. ONTANEDA D, Amezcua L
    Re-thinking race and geography in multiple sclerosis.
    Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
    >> Share

  386. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
    Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
    >> Share

  387. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
    Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
    >> Share

  388. PORWAL MH, Obeidat AZ
    A closer look at reported colitis in association with multiple sclerosis treatments.
    Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
    >> Share

  389. LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
    Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
    Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
    >> Share

  390. RAMARI C, Awadia Z, Bansi J, Casey B, et al
    The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
    Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
    >> Share

  391. DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
    The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
    Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
    >> Share

  392. MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
    The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
    Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
    >> Share

  393. ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
    The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
    Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
    >> Share

  394. MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
    The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
    Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
    >> Share

  395. ZHANG Y, Atkinson J, Burd CE, Graves J, et al
    Biological aging in multiple sclerosis.
    Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
    >> Share

  396. BEREK K, Hegen H, Auer M, Barket R, et al
    Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
    Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
    >> Share

  397. KOCH MW, Moral E, Brieva L, Mostert J, et al
    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
    Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
    >> Share

  398. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
    Vaccination frequency in people newly diagnosed with multiple sclerosis.
    Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
    >> Share

  399. REYES S, Otero-Romero S
    Rethinking vaccination in multiple sclerosis: The way forward.
    Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
    >> Share

  400. LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
    Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
    Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
    >> Share

  401. TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
    Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
    Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
    >> Share

  402. JACOBER SLS, Disanto G, Sacco R, Meng D, et al
    Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
    Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
    >> Share

  403. UHER T, Adzima A, Srpova B, Noskova L, et al
    Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
    Mult Scler. 2023;29.
    >> Share

  404. WU Y, Geraldes R, Jurynczyk M, Palace J, et al
    Double-negative neuromyelitis optica spectrum disorder.
    Mult Scler. 2023;29.
    >> Share

  405. THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
    Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
    Mult Scler. 2023;29.
    >> Share

    September 2023
  406. ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
    Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
    Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
    >> Share

  407. CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
    Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
    Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
    >> Share

  408. VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
    Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
    Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
    >> Share

  409. FREEDMAN DE, Krysko KM, Feinstein A
    Intimate partner violence and multiple sclerosis.
    Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
    >> Share

  410. CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
    A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
    Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
    >> Share

  411. MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
    Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
    Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
    >> Share

  412. KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
    Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
    >> Share

  413. BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
    Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
    >> Share

  414. MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
    GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
    >> Share

  415. MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
    The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
    Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
    >> Share

  416. WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
    Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
    Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
    >> Share

  417. BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
    Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
    >> Share

  418. HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
    Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
    >> Share

  419. DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
    Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
    Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
    >> Share

  420. GABRIELLI M, Verderio C
    Exosomal profiling should be used to monitor disease activity in MS patients: Commentary.
    Mult Scler. 2023 Sep 7:13524585231195858. doi: 10.1177/13524585231195858.
    >> Share

  421. DELTOMBE M, van Pesch V
    Exosomal profiling should be used to monitor disease activity in MS patients: No.
    Mult Scler. 2023 Sep 7:13524585231195859. doi: 10.1177/13524585231195859.
    >> Share

  422. MYCKO MP
    Exosomal profiling should be used to monitor disease activity in MS patients: Yes.
    Mult Scler. 2023 Sep 7:13524585231195860. doi: 10.1177/13524585231195860.
    >> Share

  423. CARNERO CONTENTTI E
    Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A critical view from Latin America.
    Mult Scler. 2023;29:1347-1348.
    >> Share

  424. BERHANU D, Leal Rato M, Messina S, Leite MI, et al
    The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
    Mult Scler. 2023;29:1250-1256.
    >> Share

  425. CARNERO CONTENTTI E, Lopez PA, Tkachuk V, Vrech C, et al
    Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
    Mult Scler. 2023;29:1240-1249.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016